Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dbuki who wrote (12337)	12/9/1997 12:33:00 AM
From: Zeuspaul	Respond to of 32384

Business Week Online has bumped the deal to a MAJOR deal! ..........Ready to blow ballast!....Maybe we'll see that 14 1/4 close this week. Business Week Online >> One eye-opening endorsement: Insulin market leader Eli Lilly has inked a major deal with San Diego's Ligand Pharmaceuticals to pursue retinoids.<< RECAP/SIGNAL >> Ligand Pharmaceutical's recent deal with Eli Lilly<< Good work dbuki, wires are hot!!

To: dbuki who wrote (12337)	12/9/1997 6:36:00 AM
From: Henry Niman	Respond to of 32384

dbuki, Thanks for the heads up. I looked at Business Week Online last week and didn't see anything, so I missed it. That indeed is the 2nd of the 3 articles I was expecting. I think its more upbeat than the Financial Times, and Ligand gets a bit more press. I'm not sure about the timing of the third article, but these two do add quite a bit of credibility to my source, although I was very confident on the credibility all along (in contrast to others on this thread, that don't have much of a clue about anything regarding LGND other than how to locate this site and put up repetitive posts with virtually no content).

To: dbuki who wrote (12337)	12/9/1997 6:54:00 AM
From: Henry Niman	Respond to of 32384

dbuki, Still looking for the third article, buy NY Times has a nice article on angiogenesis inhibtors today (LGND has a program, but not much news on progress in that area lately), so its clear that science articles on discoveries that lead to novel approaches for treating major diseases are still a prioity with them, and as shown by the Finacial Times and Newsweek articles, diabetes is a hot topic although the Rezulin problems, especially in the UK, has thrown on some cold water.